Comparing two diabetes drugs in real-world use
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two common diabetes medications, empagliflozin and dapagliflozin, to see which works better in everyday practice. It aims to find the best treatment option for patients with type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are able to understand and sign a consent form
- You have not withdrawn your consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
This trial compares two diabetes medications, empagliflozin and glimepiride, added to your current treatment to see which is more effective and safe for managing blood sugar. It is for adults with type 2 diabetes who have already been on oral diabetes pills for at least 8 weeks.
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.